<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940811-0-00028</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> August 11, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 556 and 558</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Animal Drugs, Feeds, and Related Products; Melengestrol Acetate  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of 12 supplemental new animal drug applications (NADA's) filed by The Upjohn Co. The applications concern the use of Type A medicated articles containing melengestrol acetate (MGA) (alone and in combination) to manufacture certain combination drug Type B and Type C medicated feeds for heifers fed in confinement for slaughter. The supplements provide for a revised tolerance of 25 parts per billion (ppb) MGA residues, which is a change in the regulation of medicated feed applications to a Category I drug, and the removal of the requirement for a 48-hour preslaughter withdrawal period. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> August 11, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Jack Caldwell, Center for Veterinary Medicine (HFV&hyph;126), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1638.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Upjohn Co., Kalamazoo, MI 49001, filed 12 supplemental NADA's revising the conditions of use of melengestrol acetate (MGA) Type A medicated articles to make Type B and Type C medicated feeds for heifers being fed in confinement for slaughter. The NADA's supplemented are:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1) NADA 34&hyph;254: MGA 100/200. <!-- PJG 0012 frnewline --> (2) NADA 39&hyph;402: MGA Liquid 500. <!-- PJG 0012 frnewline --> (3) NADA 124&hyph;309: MGA 100/200 plus Monensin. <!-- PJG 0012 frnewline --> (4) NADA 125&hyph;476: MGA 500 Liquid plus Monensin. <!-- PJG 0012 frnewline --> (5) NADA 138&hyph;792: MGA 100/200 plus Monensin and Tylosin. <!-- PJG 0012 frnewline --> (6) NADA 138&hyph;870: MGA 500 Liquid plus Monensin and Tylosin. <!-- PJG 0012 frnewline --> (7) NADA 138&hyph;904: MGA 100/200 plus Lasalocid and Tylosin. <!-- PJG 0012 frnewline --> (8) NADA 138&hyph;992: MGA 500 Liquid plus Lasalocid and Tylosin. <!-- PJG 0012 frnewline --> (9) NADA 138&hyph;995: MGA 100/200 plus Tylosin. <!-- PJG 0012 frnewline --> (10) NADA 139&hyph;192: MGA 500 Liquid plus Tylosin. <!-- PJG 0012 frnewline --> (11) NADA 139&hyph;876: MGA 100/200 plus Lasalocid. <!-- PJG 0012 frnewline --> (12) NADA 140&hyph;288: MGA 500 Liquid plus Lasalocid. <!-- PJG 0012 frnewline --> The supplements provide for the following actions: (1) Deleting the 48-hour preslaughter withdrawal period for use in heifers being fed in confinement for slaughter for increased rate of weight gain, improved feed efficiency, and suppression of estrus; (2) amending the classification in &sect;558.4  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Medicated Feed Applications <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (21 CFR 558.4) from Category II to Category I because the use of the drug no longer requires a withdrawal period; and (3) revising the tolerance for residues of MGA in uncooked, edible cattle tissues from no residue to a finite tolerance of 25 ppb. The tolerance was set based on the determination that the endpoint of toxicological concern is hormonal activity and that residues of MGA at or below 25 ppb in edible tissues of treated animals will not elicit a hormonal response. <!-- PJG 0012 frnewline --> Also, &sect;556.380 (21 CFR 556.380) includes a gas-liquid chromatographic (GLC) method of analysis for residues of MGA in tissues. That method was in the regulation recodified from food additives to animal drugs in 1970. The Official Methods of Analysis of the Association of Official Analytical Chemists (AOAC), 15th ed., 1990, in section 976.36 (pp. 629&hyph;631) provides an updated GLC method for determining MGA residues in animal tissues. The procedure is also published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Journal of the Association of Official Analytical Chemists <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , JAOAC 59: 507&hyph;515, 1976. FDA is removing the analytical method in &sect;556.380 and relying on the AOAC for the method of analysis for MGA. <!-- PJG 0012 frnewline --> These are new animal drugs used in Type A medicated articles to make Type B and C medicated feeds. With approval of these supplements, MGA is a Category I drug which, as provided in &sect;558.4, does not require an approved form FDA 1900 for making a Type B or C medicated feed from a Type A medicated article. Approved form FDA 1900's may be withdrawn at the request of the sponsor. <!-- PJG 0012 frnewline --> The supplements are approved as of June 29, 1994. 21 CFR 556.380 is revised to remove the existing text and provide for a finite tolerance. Section 558.4 is revised to remove the MGA entry from the Category II table and add it to the Category I table. 21 CFR 558.342 is amended by revising paragraphs (c)(1)(ii), (c)(2)(ii), (c)(3)(ii), (c)(4)(ii), (c)(5)(ii), and (c)(6)(ii), and 21 CFR 558.355 is amended by revising paragraphs (f)(3)(iv)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) and (f)(3)(viii) to remove the 48-hour preslaughter withdrawal statement. <!-- PJG 0012 frnewline --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), these supplements for food-producing animals do not qualify for marketing exclusivity because the supplements do not contain new clinical or field investigations (other than bioequivalence or residue studies) and new human food safety studies (other than bioequivalence or residue studies) essential to the approval and conducted or sponsored by the applicant. <!-- PJG 0012 frnewline --> The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 -->  21 CFR Part 556 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Animal drugs, Foods. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 -->  21 CFR Part 558 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Animal drugs, Animal feeds. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 556 and 558 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 556_TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 556 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> : Secs. 402, 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 342, 360b, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 556.380 is revised to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;556.380  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Melengestrol acetate. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A tolerance of 25 parts per billion is established for residues of the parent compound, melengestrol acetate, in fat of cattle.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 558_NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. The authority citation for 21 CFR part 558 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> : Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. Section 558.4 is amended in paragraph (d) in the ``Category I'' table by alphabetically adding a new entry for ``melengestrol acetate'' and in the ``Category II'' table by removing the entry for ``melengestrol acetate'' to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;558.4  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Medicated feed applications. <!-- PJG 0012 frnewline -->  <!-- PJG 0011 horztab -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 -->  * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (d) *&blank;*&blank;* <!-- PJG 0012 frnewline -->  <!-- PJG 0011 horztab -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 -->  * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 4,L1,i1,s40,10C,r30,30C -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Category <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  I <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Drug  <!-- PJG 007 0150 intable --> 1Assay limits percent <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=1 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  type A  <!-- PJG 007 0150 intable --> 1Type B maximum (200x)  <!-- PJG 007 0150 intable --> 1Assay limits percent <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=1 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  type B/C <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> Melengestrol acetate  <!-- PJG 007 0104 intable --> 90&hyph;110  <!-- PJG 007 0104 intable --> 10.0 g/ton (0.0011%)  <!-- PJG 007 0104 intable --> 70&hyph;120 <!-- PJG /ITAG -->  <!-- PJG QTAG 03 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 007 0146 intable --> 1Percent of labeled amount. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> 2Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make Type C medicated feed. <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0011 horztab -->  <!-- PJG ITAG l=37 g=1 f=1 -->  * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;558.342  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> [Amended] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 5. Section 558.342  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Melengestrol acetate <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is amended in paragraphs (c)(1)(ii), (c)(2)(ii), (c)(3)(ii), (c)(4)(ii), (c)(5)(ii), and (c)(6)(ii), by removing the sentence ``Withdraw melengestrol acetate 48 hours prior to slaughter.'' each time it appears. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;558.355  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> [Amended] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 6. Section 558.355  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Monensin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is amended in paragraph (f)(3)(iv)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) by removing the sentence ``Withdraw melengestrol acetate 48 hours prior to slaughter.'', and in paragraph (f)(3)(viii) by removing the last sentence ``Medicated feeds containing melengestrol acetate are required to be withdrawn 48 hours prior to slaughter.'' <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 4, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Robert C. Livingston, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;19656 Filed 8&hyph;10&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            